Histamine-induced plasticity and gene expression in corticostriatal pathway under hyperammonemia.
- Authors
- Type
- Published Article
- Journal
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley (Blackwell Publishing)
- Publication Date
- Mar 01, 2020
- Volume
- 26
- Issue
- 3
- Pages
- 355–366
- Identifiers
- DOI: 10.1111/cns.13223
- PMID: 31571389
- Source
- Medline
- Keywords
- Language
- English
- License
- Unknown
Abstract
Histamine H3 receptor (H3R) antagonists/inverse agonists increase vigilance. We studied brain histaminergic pathways under hyperammonemia and the transcriptome of receptors and their signaling cascades to provide a rationale for wake-promoting therapies. We analyzed histamine-induced long-lasting depression of corticostriatal synaptic transmission (LLDhist). As the expression of dopamine 1 receptors (D1R) is upregulated in LGS-KO striatum where D1R-H3R dimers may exist, we investigated actions of H3R and D1R agonists and antagonists. We analyzed transcription of selected genes in cortex and dorsal striatum in a mouse model of inborn hyperammonemia (liver-specific glutamine synthetase knockout: LGS-KO) and compared it with human hepatic encephalopathy. LGS-KO mice showed significant reduction of the direct depression (DD) but not the long-lasting depression (LLD) by histamine. Neither pharmacological activation nor inhibition of D1R significantly affected DDhist and LLDhist in WT striatum, while in LGS-KO mice D1R activation suppressed LLDhist. Histaminergic signaling was found unchanged at the transcriptional level except for the H2R. A study of cAMP-regulated genes indicated a significant reduction in the molecular signature of wakefulness in the diseased cortex. Our findings provide a rationale for the development of aminergic wake-promoting therapeutics in hyperammonemic disorders. © 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.